AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
18.6.2020 03:00:00 EEST | Business Wire | Press release
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
About AR1001
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005630/en/
Contact information
Fred Kim
734-516-8732
fredkim@aribiousa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Measuring Muscles with Quantitative MRI: New Study Published in Neurology Expands the Evidence for Using MRI Biomarkers in SBMA26.8.2026 15:27:00 EEST | Press release
AMRA Medical is pleased to announce the publication of new research in Neurology demonstrating the potential of quantitative whole-body MRI to measure disease progression in Spinal and Bulbar Muscular Atrophy (SBMA), a rare, progressive neuromuscular disease. The research was also selected for the cover of the issue, providing additional visibility for this important work in neuromuscular disease research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826386576/en/ AMRA Medical - Measuring Muscles with Quantitative MRI The manuscript, titled “Muscle MRI as an imaging biomarker of muscle damage in patients with spinal and bulbar muscular atrophy” highlights how MRI-based muscle composition biomarkers can provide sensitive and objective measures of disease-related change over time. With AMRAⓇ Researcher, the study evaluated 25 participants with SBMA to investigate the ability of fat-referenced MRI to assess changes in musc
KEWPIE IT. London discovers the Mayo behind the Iconic Tamago Sando26.8.2026 15:10:00 EEST | Press release
Kewpie Corporation(TOKYO:2809) is inviting Londoners to discover how one simple squeeze can transform one of the world's most iconic sandwiches. Through a new experiential pop-up in Covent Garden Piazza, the iconic Japanese mayonnaise brand is bringing its rich, creamy, umami flavour to the heart of London's food scene, celebrating the ingredient that elevates the Tamago Sando AKAthe iconic Japanese Egg Sandwich. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826081552/en/ An image of the pop-up scheduled to take place at Covent Garden Piazza in London KEWPIE MAYONNAISE is mostly made with egg yolks (not whole eggs), which is responsible for its richness and umami flavour, alongside their proprietary vinegars. With its signature bottle and unique taste, KEWPIE MAYONNAISE has earned a loyal following among chefs and food lovers for its distinctive richness and depth of flavour. Rather than following food trends, the brand
Copeland Appoints Sandro Matic as President, Americas, and Gwen Cheramy as President, Europe26.8.2026 15:00:00 EEST | Press release
Copeland, a global provider of compression technologies and controls solutions, today announced that Gwen Cheramy will join the company as President of its Europe business on Oct. 1, 2026, and that Sandro Matic will assume the role of President of its Americas business on Sept. 1, 2026. Matic will continue to lead Europe on an interim basis until Cheramy joins Copeland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826567313/en/ Sandro Matic, President, Americas for Copeland "Sandro and Gwen are both proven leaders with strong track records of delivering results within our industry,” said Ross B. Shuster, CEO of Copeland. "In their new roles, they will be instrumental in providing leadership to our local colleagues, supporting our customers, and advancing Copeland’s strategic priorities across their respective regions while helping execute our global strategy.” Matic joined the business in 2011, initially with Emerson, a
NetApp Named a Leader in the 2026 Gartner® Magic Quadrant™ for Enterprise Storage Platforms26.8.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2026 Gartner Magic Quadrant for Enterprise Storage Platforms, continuing to acknowledge NetApp as a Leader in this market from its inaugural edition of this report in 2025. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. Additionally, the 2026 Gartner Critical Capabilities for Enterprise Storage Platforms report ranks NetApp first in the Hybrid Cloud Storage Use Case and second in the Hybrid Platform Services Use Case. NetApp believes this recognition validates the company’s ability to help customers address their most pressing data challenges while offering more predictable hardware delivery timelines than its competitors. The NetApp Platform is an intelligent, governed foundation that provides zero-copy access to an organization’s data, wherever it resides. It enables
Pure Lithium Announces Unprecedented Cycling Results From Its Advanced Anode™ Lithium Metal Battery Technology26.8.2026 14:00:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, today announced that our Advanced Anode™ battery, technology developed specifically to enable ultra-long cycling, has achieved more than 9,315 cycles. The cells continue to cycle in the Company's laboratory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826201214/en/ To the Company’s knowledge, no other lithium metal battery in development has achieved such results under equivalent testing conditions. The performance of the Company’s battery, achieved with negligible capacity fade, far exceeds today’s commercial lithium-ion battery cycling requirements across numerous applications, where performance typically ranges from 250 to 2,000 cycles, depending on the application. These results were achieved at 100% depth of discharge, and charge rates of 1C: 1C.1 “The results of Pure Lithium’s cycling performance are disruptive. Cycle life
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom